The clearance is for Quidel’s non-instrumented molecular diagnostic test: the AmpliVue C. difficile Assay. It is designed for the detection of toxigenic C. difficile bacterial DNA.
The company says detection of the pathogen is achieved using a hand-held, fully contained cassette that combines isothermal Helicase Dependent Amplification with its lateral flow detection technology.
“We are very pleased to receive 510(k) clearance for the first hand-held molecular device for C. difficile,” said Douglas Bryant, president and CEO of Quidel Corp. in the release. “The AmpliVue C. difficile Assay will allow hospitals currently using traditional detection methods to employ a more sensitive, rapid molecular test, thereby providing laboratory technicians and the physicians they serve with accurate, timely, and reliable diagnosis of C. difficile infections.”
Related Articles on FDA Clearances:
Lutronic Receives FDA Clearance for Phototherapy System
Halt Medical Receives FDA Clearance for System to Treat Uterine Fibroids
aap Implantate AG Receives FDA Clearance for Trauma Plating System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
